JP2005027667A5 - - Google Patents

Download PDF

Info

Publication number
JP2005027667A5
JP2005027667A5 JP2004186386A JP2004186386A JP2005027667A5 JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5 JP 2004186386 A JP2004186386 A JP 2004186386A JP 2004186386 A JP2004186386 A JP 2004186386A JP 2005027667 A5 JP2005027667 A5 JP 2005027667A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
antibody
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004186386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005027667A (ja
JP4252501B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005027667A publication Critical patent/JP2005027667A/ja
Publication of JP2005027667A5 publication Critical patent/JP2005027667A5/ja
Application granted granted Critical
Publication of JP4252501B2 publication Critical patent/JP4252501B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004186386A 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法 Expired - Fee Related JP4252501B2 (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US13838599P 1999-06-09 1999-06-09
US14479099P 1999-07-20 1999-07-20
US14684399P 1999-08-03 1999-08-03
US14818899P 1999-08-10 1999-08-10
US14932799P 1999-08-17 1999-08-17
US14939699P 1999-08-17 1999-08-17
US14932099P 1999-08-17 1999-08-17
US15011499P 1999-08-20 1999-08-20
US15170099P 1999-08-31 1999-08-31
US15173499P 1999-08-31 1999-08-31

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001502580A Division JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005181588A Division JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Division JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2005027667A JP2005027667A (ja) 2005-02-03
JP2005027667A5 true JP2005027667A5 (enExample) 2005-09-22
JP4252501B2 JP4252501B2 (ja) 2009-04-08

Family

ID=27581055

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001502580A Pending JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法
JP2004186386A Expired - Fee Related JP4252501B2 (ja) 1999-06-09 2004-06-24 腫瘍の治療のための組成物と方法
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001502580A Pending JP2003501087A (ja) 1999-06-09 2000-05-15 腫瘍の治療のための組成物と方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005181588A Pending JP2006006332A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181534A Expired - Lifetime JP4260778B2 (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法
JP2005181558A Pending JP2006006331A (ja) 1999-06-09 2005-06-22 腫瘍の治療のための組成物と方法

Country Status (8)

Country Link
EP (3) EP1657256B1 (enExample)
JP (5) JP2003501087A (enExample)
AT (2) ATE444971T1 (enExample)
AU (1) AU4851900A (enExample)
CA (1) CA2371434A1 (enExample)
DE (2) DE60043125D1 (enExample)
ES (2) ES2332916T3 (enExample)
WO (1) WO2000075317A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
US6960651B2 (en) 1999-06-29 2005-11-01 Millennium Pharmaceuticals, Inc. TANGO 332 polypeptides
AU1473801A (en) * 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 6 human secreted proteins
AU2463401A (en) * 1999-12-29 2001-07-09 Zymogenetics Inc. Novel fgf homolog zfgf10
US20020001825A1 (en) * 2000-03-31 2002-01-03 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
JP2004520005A (ja) * 2000-06-19 2004-07-08 エフ.ホフマン−ラ ロシュ アーゲー オステオレビン遺伝子多型性
WO2003073991A2 (en) * 2002-03-01 2003-09-12 Celltech R & D, Inc. Methods to increase or decrease bone density
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
US9145457B2 (en) 2011-03-25 2015-09-29 Amgen Inc. Sclerostin antibody crystals and formulations thereof
ES2667554T3 (es) 2011-08-04 2018-05-11 Amgen Inc. Método para el tratamiento de los defectos de espacio óseo
KR20190120401A (ko) 2011-12-28 2019-10-23 암젠 인크 항스클레로스틴 항체의 이용을 통한 치조골 소실의 치료 방법
JP6770312B2 (ja) 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
DE69333202T2 (de) * 1992-06-26 2004-03-18 The Trustees Of Princeton University Verfahren zur erkennung von krebszellen oder ihren vorstadien mittels p90 und p53-antikörper oder p90 und p53-sonden
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
US5635370A (en) * 1994-04-08 1997-06-03 Yale University DNA encoding BEHAB, a brain hyaluronan-binding protein, and recombinant expression systems for production of BEHAB polypeptides
WO1999014327A2 (en) * 1997-09-17 1999-03-25 Genentech, Inc. Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer
AU5923398A (en) * 1997-01-21 1998-08-07 Human Genome Sciences, Inc. Polynucleotides and polypeptides encoding receptors
EP1032668B1 (en) * 1997-11-25 2008-05-28 Genentech, Inc. Fibroblast growth factor-19
KR20010086224A (ko) * 1998-01-23 2001-09-10 추후제출 Meth1 및 meth2 폴리뉴클레오티드 및 폴리펩티드
AU5619700A (en) * 1999-06-29 2001-01-31 Millennium Pharmaceuticals, Inc. Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses

Similar Documents

Publication Publication Date Title
CA2479494A1 (en) Compositions and methods associated with pro5725 and its use for the diagnosis of lung and colon tumor
US7198899B2 (en) Use of NRG4, or inhibitors thereof, in the treatment of colon and pancreatic cancers
JP2006081548A5 (enExample)
JP2008301822A5 (enExample)
JP2005522986A5 (enExample)
CA2679954A1 (en) Assessment of risk for colorectal cancer
JP2009519002A5 (enExample)
CA2486252A1 (en) Methods for screening for agents that modulate hepatocellular carcinoma development
JP2005046146A5 (enExample)
KR20060125923A (ko) 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
JP2009001563A5 (enExample)
WO1999033963A1 (en) Metastatic cancer regulated gene
JP2005535601A5 (ja) 可溶型の炭酸脱水酵素IX(s-CA IX)、s-CA IXを検出するためのアッセイ、CA IXとHER-2/neu/c-erbB-2の同時発現、非免疫優性エピトープに対するCA IX特異的モノクローナル抗体
AU2007319360A1 (en) Methods of treating, diagnosing or detecting cancer
CN107001480B (zh) 用于人c-maf的结合成员
JP2009039107A5 (enExample)
JP2021046417A (ja) 抗Aggrusモノクローナル抗体、CLEC−2との結合に必要なAggrusの領域、及びAggrus−CLEC‐2結合阻害剤のスクリーニング方法
US20050064440A1 (en) Methods for identifying risk of melanoma and treatments thereof
JP2004138610A5 (enExample)
US8962808B2 (en) EGFR-related polypeptides and methods of use
WO2004074511A1 (en) Diagnosis and treatment of baff-mediated autoimmune diseases and cancer
JP2004513614A5 (enExample)
US20050277118A1 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
TW202535930A (zh) 同功型選擇性抗-TGF-β 抗體及其使用方法
JP2007508020A5 (enExample)